<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 7, 2000
--------------
InKine Pharmaceutical Company, Inc.
--------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
<TABLE>
<CAPTION>
New York 0-24972 13-3754005
------------------------------------------------------------------------------------
<S> <C> <C>
(State or Other Jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation) Identification No.)
</TABLE>
1720 Walton Road, Suite 200, Blue Bell, Pennsylvania 19422
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (610) 260-9350
--------------
<PAGE>
Item 8. Change in Fiscal Year
Attached hereto as Exhibit 99.1 is a press release issued by InKine
Pharmaceutical Company, Inc. (the "Company") on August 9, 2000 announcing the
change of its fiscal year-end from June 30 to a calendar year-end of December
31. The Company's quarterly reporting periods will end on March 31, June 30 and
September 30. The Company will file a Transition Report on Form 10-K for the
interim period (July 1, 2000 through December 31, 2000). In addition, the
Company will file a Quarterly Report on Form 10-Q for the three month period
ending September 30, 2000.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
INKINE PHARMACEUTICAL COMPANY, INC.
By: /s/ Robert F. Apple
-------------------------------------------------
Robert F. Apple
Senior Vice President and Chief Financial Officer
Dated: August 11, 2000
-2-
<PAGE>
EXHIBIT INDEX
Exhibit No. Title
----------- -----
99.1 Press Release, dated August 9, 2000.
